These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23344547)

  • 21. Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database.
    Zhou J; Sirisanthana T; Kiertiburanakul S; Chen YM; Han N; Lim PL; Kumarasamy N; Choi JY; Merati TP; Yunihastuti E; Oka S; Kamarulzaman A; Phanuphak P; Lee CK; Li PC; Pujari S; Saphonn V; Law MG
    BMC Infect Dis; 2010 Dec; 10():361. PubMed ID: 21182796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation and Operational Research: CD4 Count Monitoring Frequency and Risk of CD4 Count Dropping Below 200 Cells Per Cubic Millimeter Among Stable HIV-Infected Patients in New York City, 2007-2013.
    Myers JE; Xia Q; Torian LV; Irvine M; Harriman G; Sepkowitz KA; Shepard CW
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):e73-8. PubMed ID: 26536317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinician-nurse model to reduce early mortality and increase clinic retention among high-risk HIV-infected patients initiating combination antiretroviral treatment.
    Braitstein P; Siika A; Hogan J; Kosgei R; Sang E; Sidle J; Wools-Kaloustian K; Keter A; Mamlin J; Kimaiyo S
    J Int AIDS Soc; 2012 Feb; 15(1):7. PubMed ID: 22340703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia.
    Chi BH; Giganti M; Mulenga PL; Limbada M; Reid SE; Mutale W; Stringer JS
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):125-31. PubMed ID: 19546812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa.
    McGrath N; Lessells RJ; Newell ML
    HIV Med; 2015 Sep; 16(8):512-8. PubMed ID: 25959724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.
    Hoffmann CJ; Fielding KL; Charalambous S; Innes C; Chaisson RE; Grant AD; Churchyard GJ
    AIDS; 2010 Jul; 24(11):1709-16. PubMed ID: 20495439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
    Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
    N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
    Murray M; Hogg RS; Lima VD; May MT; Moore DM; Abgrall S; Bruyand M; D'Arminio Monforte A; Tural C; Gill MJ; Harris RJ; Reiss P; Justice A; Kirk O; Saag M; Smith CJ; Weber R; Rockstroh J; Khaykin P; Sterne JA;
    HIV Med; 2012 Feb; 13(2):89-97. PubMed ID: 21819529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.
    Cornell M; Johnson LF; Wood R; Tanser F; Fox MP; Prozesky H; Schomaker M; Egger M; Davies MA; Boulle A;
    J Int AIDS Soc; 2017 Sep; 20(1):21902. PubMed ID: 28953328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.
    Le T; Wright EJ; Smith DM; He W; Catano G; Okulicz JF; Young JA; Clark RA; Richman DD; Little SJ; Ahuja SK
    N Engl J Med; 2013 Jan; 368(3):218-30. PubMed ID: 23323898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.
    Phillips AN; Eron JJ; Bartlett JA; Rubin M; Johnson J; Price S; Self P; Hill AM
    AIDS; 1996 Jul; 10(8):859-65. PubMed ID: 8828743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy.
    McManus H; O'Connor CC; Boyd M; Broom J; Russell D; Watson K; Roth N; Read PJ; Petoumenos K; Law MG;
    PLoS One; 2012; 7(11):e48839. PubMed ID: 23144991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.
    De Luca A; Marazzi MC; Mancinelli S; Ceffa S; Altan AM; Buonomo E; Prosperi MC; Pedruzzi B; Noorjehan AM; Scarcella P; Liotta G; Palombi L
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):236-44. PubMed ID: 22327246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy.
    Zhang S; van Sighem A; Kesselring A; Gras L; Smit C; Prins JM; Kauffmann R; Richter C; de Wolf F; Reiss P
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):265-72. PubMed ID: 22531756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients.
    Maskew M; Brennan AT; Westreich D; McNamara L; MacPhail AP; Fox MP
    J Womens Health (Larchmt); 2013 Feb; 22(2):113-20. PubMed ID: 23350862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.